Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus rating of “H...
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near...
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) have earned a consensus rating of "H...
Myriad Genetics, Inc. (NASDAQ: MYGN) stands at a pivotal moment in the healthcare diagnostics sector...
On Wednesday, 11 June 2025, Myriad Genetics (NASDAQ:MYGN) participated in the Goldman Sachs 46th Ann...